Robert A. Anders
0000-0002-2363-9072
Publication & Citation Trends
Publications
0 total
Evaluating diagnosis and clinical outcome for antibody-mediated rejection in liver transplantation: performance of the 2016 Banff Working Group criteria.
Cited by 0
Semantic Scholar
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDAC.
Cited by 0
Semantic Scholar
Context-dependent inhibitory roles of RhoA in 3D invasive cell migration within the extracellular matrix
Cited by 0
Semantic Scholar
A fixation-compatible protocol for intracellular and surface marker-based detection of circulating tumor cells in hepatocellular carcinoma
Cited by 0
Semantic Scholar
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Cited by 6
Semantic Scholar
Neoadjuvant immunotherapy promotes the formation of mature tertiary lymphoid structures in a remodeled pancreatic tumor microenvironment.
Cited by 5
Semantic Scholar
A phase II study of neoadjuvant GVAX and cyclophosphamide combined with nivolumab and SBRT followed by surgery in borderline resectable pancreatic adenocarcinoma.
Cited by 2
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(235)
Pancreatic and Hepatic Oncology Research
(83)
Cancer Genomics and Diagnostics
(81)
Immunotherapy and Immune Responses
(80)
Liver Disease Diagnosis and Treatment
(75)
Affiliations
Novartis (Switzerland)
United States Geological Survey
Bloomberg (United States)
Apple (Israel)
Mayo Clinic